Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Innate Pharma S.A. before investing.

In this article, we go over a few key elements for understanding Innate Pharma S.A.’s stock price such as:

• Innate Pharma S.A.’s current stock price and volume
• Why Innate Pharma S.A.’s stock price changed recently
• Upgrades and downgrades for IPHA from analysts
• IPHA’s stock price momentum as measured by its relative strength

About Innate Pharma S.A. (IPHA)

Before we jump into Innate Pharma S.A.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Want to learn more about Innate Pharma S.A.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Innate Pharma S.A..

What Caused Innate Pharma S.A. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2026, there were analysts who downgraded Innate Pharma S.A.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Innate Pharma S.A.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Innate Pharma S.A.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Innate Pharma S.A. (IPHA) by visiting AAII Stock Evaluator.

Relative Price Strength of Innate Pharma S.A.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2026, Innate Pharma S.A. has a weighted four-quarter relative price strength of -15.90%, which translates to a Momentum Score of 15 and is considered to be Very Weak.

Want to learn more about how Innate Pharma S.A. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Innate Pharma S.A. Stock Price: Bottom Line

As of May 1, 2026, Innate Pharma S.A.’s stock price is $1.540, which is up 6.94% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Innate Pharma S.A. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.